VOICED : Acuerdo para facilitar el acceso mundial a la píldora anticovid de Pfizer

Pfizer has signed a voluntary license agreement to distribute its COVID-19 antiviral pill beyond wealthy countries, allowing generic manufacturers to supply the medication to 95 countries, covering 53% of the global population. The pill, developed with BioNTech, shows 89% efficacy in preventing severe COVID-19 outcomes. This move parallels Merck's similar agreement for its antiviral, Monlupiravir. Both treatments require a 10-dose regimen over five days and have minimal side effects.

What is the main purpose of Pfizer's voluntary license agreement?

• To collaborate with Merck on a joint treatment

• To limit the distribution to only European countries

• To increase the price of the COVID-19 pill

• To facilitate access to the pill beyond wealthy countries

How many countries are expected to benefit from the distribution of Pfizer's COVID-19 pill?

• 95 countries

• 50 countries

• 75 countries

• 120 countries

What percentage of the global population is covered by the agreement for Pfizer's COVID-19 pill?

• 53%

• 25%

• 75%

• 90%

What is the reported efficacy of Pfizer's antiviral pill in preventing severe COVID-19 outcomes?

• 70%

• 80%

• 95%

• 89%

How do Pfizer's and Merck's antiviral treatments compare in terms of dosage?

• Both require a single dose

• Merck's requires 5 doses, Pfizer's requires 15

• Both require 10 doses over five days

• Pfizer's requires 5 doses, Merck's requires 10